Coign Capital Advisors LLC Takes $598,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Coign Capital Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,637 shares of the medical instruments supplier's stock, valued at approximately $598,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Becton, Dickinson and Company by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier's stock worth $6,067,196,000 after purchasing an additional 184,288 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Becton, Dickinson and Company by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock worth $1,437,161,000 after acquiring an additional 66,024 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Becton, Dickinson and Company by 15.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock valued at $1,401,126,000 after acquiring an additional 810,345 shares during the last quarter. First Eagle Investment Management LLC raised its stake in shares of Becton, Dickinson and Company by 31.4% in the 4th quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock valued at $1,004,132,000 after acquiring an additional 1,057,879 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Becton, Dickinson and Company by 6.7% in the 4th quarter. Invesco Ltd. now owns 4,265,638 shares of the medical instruments supplier's stock worth $967,745,000 after purchasing an additional 267,436 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

A number of equities analysts have recently commented on BDX shares. Barclays dropped their price objective on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a research note on Monday, April 7th. Piper Sandler increased their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a research report on Tuesday, January 28th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Buy" and a consensus target price of $275.71.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the transaction, the executive vice president now owns 4,887 shares in the company, valued at $964,107.36. The trade was a 8.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bertram L. Scott sold 700 shares of the firm's stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total transaction of $159,593.00. Following the sale, the director now owns 36,033 shares in the company, valued at $8,215,163.67. This trade represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,675 shares of company stock worth $1,057,182 in the last three months. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Price Performance

BDX traded down $3.69 during midday trading on Tuesday, hitting $202.02. The company had a trading volume of 2,567,831 shares, compared to its average volume of 1,691,214. Becton, Dickinson and Company has a twelve month low of $193.03 and a twelve month high of $251.99. The firm's 50-day simple moving average is $223.18 and its 200-day simple moving average is $229.56. The company has a market capitalization of $58.01 billion, a PE ratio of 33.56, a P/E/G ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Monday, March 10th were given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.06%. The ex-dividend date of this dividend was Monday, March 10th. Becton, Dickinson and Company's payout ratio is 69.10%.

Becton, Dickinson and Company declared that its board has authorized a share repurchase program on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company's leadership believes its stock is undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.